+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 31 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating Risvutatug rezetecan Ris-Rez, a new medicine targeting specific proteins B7-H3 on cancer cells, in people with relapsed small cell lung cancer SCLC. The study compares Ris-Rez with the standard treatment topotecan to see if Ris-Rez can shrink tumors or make them disappear and if it helps participants live longer. It also examines the safety and side effects of both treatments to better understand their impact. Participants with relapsed SCLC will be randomly assigned to receive either Ris-Rez or topotecan. Both treatments will be administered according to standard protocols, with Ris-Rez provided as a biological therapy and topotecan as a drug treatment. The study is open-label, meaning both participants and researchers know which treatment is given. During the study, participants will be monitored through various assessments including survival time, tumor response, symptom changes, brain progression, and quality of life measures. Safety will be closely tracked through adverse event reports, laboratory tests, heart function evaluations, and immune response monitoring. The main outcome focuses on overall survival, with follow-up extending up to approximately 113 weeks to capture long-term effects and responses.

Age: 18Years +All GendersPhase 3
144 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of ONO-2020 in treating agitation associated with Alzheimers Disease dementia in patients aged 55 to 90 years in Japan. This phase 2a, multicenter, randomized, double-blind, placebo-controlled study aims to better understand how ONO-2020 affects agitation symptoms in this population. Participants will be randomly assigned to receive either two tablets of ONO-2020 or matching placebo once daily. This treatment will continue for up to 12 weeks, with monitoring of safety and efficacy measures during and up to 16 weeks from the start. The study includes close observation for adverse events and vital signs, as well as laboratory and ECG monitoring. Throughout the trial, participants will undergo assessments including agitation severity using the Cohen-Mansfield Agitation Inventory CMAI, cognitive function tests like the Mini Mental State Exam MMSE, and neuropsychiatric evaluations. Safety will be monitored through vital signs, ECGs, laboratory tests, and the Columbia-Suicide Severity Rating Scale. The total participation period covers up to 16 weeks, including treatment and follow-up assessments.

Age: 55Years - 90YearsAll GendersPhase 2
39 locations
E

Actively Recruiting

Researchers are studying chronic migraine, a condition causing moderate to severe headaches often on one side of the head, sometimes with nausea, vomiting, and sensitivity to light or sound. This trial evaluates how well the medicine atogepant works compared to a placebo in preventing chronic migraine in participants aged 12 to 17 years. The study also monitors adverse events to assess safety. Participants will be randomly assigned to receive either oral atogepant tablets or placebo once daily for 12 weeks. This double-blind study means neither the participants nor the doctors know who receives the medicine or placebo. Following the treatment, participants will be observed for an additional 4 weeks. During the study, participants will visit hospitals or clinics regularly for assessments. They will complete daily diaries, undergo medical evaluations, blood tests, side effect checks, and questionnaires. The main outcomes include tracking adverse events and changes in monthly migraine days, along with measures of headache days, medication use, and quality of life over approximately 16 weeks.

Age: 12Years - 17YearsAll GendersPhase 3
66 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.

Age: 6Years - 17YearsAll GendersPhase 3
98 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.

Age: 18Years - 65YearsAll GendersPhase 3
184 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of a fixed combination of follitropin alfa and lutropin alfa compared to human menopausal gonadotropin hMG in Japanese women with luteinizing hormone LH and follicle stimulating hormone FSH deficiency undergoing assisted reproductive technology ART. The study focuses on women who are premenopausal and wish to conceive, addressing fertility challenges related to these hormone deficiencies. This is a Phase 3 interventional trial with a randomized, parallel-group design. Participants will be assigned to one of two groups one receiving a fixed combination of recombinant follitropin alfa and lutropin alfa in a 21 ratio, and the other receiving hMG. Both treatments are administered daily by subcutaneous injection during ovarian stimulation, up to 18 days. Additional medications include daily cetrorelix acetate starting on Day 5 or 6 of stimulation to prevent premature ovulation, and coriongonadotropin alfa for final follicular maturation. After oocyte retrieval, participants will self-administer progesterone gel intravaginally for luteal phase support. During the study, participants will undergo assessments such as ultrasound scans to monitor follicle development, hormone level evaluations, and semen analysis of the male partner. Researchers will track the total number of oocytes retrieved, dosage and duration of gonadotropin treatment, embryo development, pregnancy rates, and safety outcomes including adverse events and ovarian hyperstimulation syndrome. The total study duration is about 5.5 months for those not becoming pregnant and up to 13 months for those with confirmed pregnancy.

Age: 18Years - 42YearsFEMALEPhase 3
21 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of adding KarXT to existing treatments for mania in adults with Bipolar-I Disorder. This trial focuses on participants experiencing an acute manic episode, with or without mixed features, who are already taking lithium, valproate, or lamotrigine. The study aims to improve mania symptoms, measured by changes in the Young Mania Rating Scale after five weeks. Participants will be randomly assigned to receive either KarXT in addition to their mood stabilizer or a placebo plus their mood stabilizer. The treatments are given in specified doses over the study period, with careful monitoring of side effects and other health measures. The study includes a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants will undergo regular assessments including psychiatric evaluations, rating scales for mania and other symptoms, and safety monitoring up to seven weeks. Researchers will track symptom changes, treatment responses, and any adverse events. Participants are involved in scheduled visits for evaluations and to maintain stable mood stabilizer doses. The total participation lasts until the primary outcome is measured at week five, with additional safety follow-up up to week seven.

Age: 18Years - 65YearsAll GendersPhase 3
109 locations
A

Actively Recruiting

Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.

Age: 40Years +All GendersPhase 2
367 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the AGENT Drug-Coated Balloon DCB compared to standard percutaneous coronary intervention PCI treatments like drug-eluting stents DES and balloon angioplasty in patients with new de novo coronary artery lesions. This open-label, randomized controlled study includes a pharmacokinetic sub-study and an intravascular ultrasound sub-study to provide additional insights. Participants will be randomly assigned to receive either the AGENT DCB or standard care, which may include drug-eluting stents or balloon angioplasty. The study covers different lesion types such as small vessel, bifurcation with side branches, and long lesions, with treatments tailored accordingly. The procedures are performed as part of PCI, and treatment allocation is done in parallel groups. During the trial, participants will undergo follow-up evaluations to monitor lesion outcomes and safety, including assessments up to 12 months after the procedure. Researchers will measure the rate of target lesion failure at 12 months as the primary outcome. Participants will also be monitored for adherence to protocol and any adverse events, with the overall study lasting until March 2032.

Age: 18Years +All GendersPhase Not Applicable
71 locations

1-10 of 31

1